Genetic Background of Polycythemia Vera
Polycythemia vera belongs to myeloproliferative neoplasms, essentially by affecting the erythroblastic lineage. JAK2 alterations have emerged as major driver mutations triggering PV-phenotype with the <i>V617F</i> mutation detected in nearly 98% of cases. That’s why JAK2 targeting therap...
Main Authors: | Mathilde Regimbeau, Romain Mary, François Hermetet, François Girodon |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-04-01
|
Series: | Genes |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4425/13/4/637 |
Similar Items
-
Polycythemia vera: Correlation of JAK2V617F mutation with clinicohematologic characteristics. A single centre experience.
by: Deepti Mutreja, et al.
Published: (2014-08-01) -
Diagnosis of exon 12‐positive polycythemia vera rescued by NGS
by: Antoine Geay, et al.
Published: (2020-05-01) -
Serum erythropoietin in the evaluation of erythrocytosis: How much does it contribute to the diagnosis of polycythemia vera?
by: Ruchi Gupta, et al.
Published: (2023-01-01) -
The utility of testing erythropoietin level in polycythemia diagnosis
by: Abdellatif Ismail, et al.
Published: (2023-12-01) -
A remarkable hematological and molecular response pattern in a patient with polycythemia vera during combination therapy with simvastatin and alendronate
by: Anders Lindholm Sørensen, et al.
Published: (2016-01-01)